🌍·8h agodiscovery
Roche Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) have successfully completed negotiations for Itovebi® (inavolisib), a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Publisher
A
AOL.com
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- AOL.com
- Region
- Global
- Scope
- discovery
- Published
- July 10, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
Leave the platform to read the original full article on the publisher site.
Source: AOL.com
Scope: discovery
Related coverage
More related coverage
RTTNews/3h ago
Weekly Buzz: JNJ, VERA Get FDA Nod; VRTX Snaps Up CRNX; MSLE Aces DMD Trial; IONS Misses Key Goal
MarketBeat/3h ago
Biotech Stocks To Keep An Eye On - July 10th
24/7 Wall St./3h ago
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout
marketscreener.com/3h ago